PE20080991A1 - Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas - Google Patents
Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlasInfo
- Publication number
- PE20080991A1 PE20080991A1 PE2007000810A PE2007000810A PE20080991A1 PE 20080991 A1 PE20080991 A1 PE 20080991A1 PE 2007000810 A PE2007000810 A PE 2007000810A PE 2007000810 A PE2007000810 A PE 2007000810A PE 20080991 A1 PE20080991 A1 PE 20080991A1
- Authority
- PE
- Peru
- Prior art keywords
- hydrochlorothiazide
- amlodipine
- valsartan
- layer
- solid dosage
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000007909 solid dosage form Substances 0.000 title abstract 2
- 229940051539 amlodipine and hydrochlorothiazide valsartan Drugs 0.000 title 1
- 239000010410 layer Substances 0.000 abstract 4
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 3
- 229960000528 amlodipine Drugs 0.000 abstract 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 abstract 2
- 229960002003 hydrochlorothiazide Drugs 0.000 abstract 2
- UIYUUEDFAMZISF-FTBISJDPSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;(2s)-3-methyl-2-[pentanoyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NNN=N1 UIYUUEDFAMZISF-FTBISJDPSA-N 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000002356 single layer Substances 0.000 abstract 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1
- 229960004699 valsartan Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA FORMA DE DOSIFICACION SOLIDA QUE COMPRENDE LA COMBINACION DE a)VARSARTAN EN UNA CANTIDAD APROXIMADA DE 80 A 640 MG; b)AMLODIPINA BAJO LA FORMA DE BESILATO EN UNA CANTIDAD APROXIMADA DE 2,5 A 20 MG; E c)HIDROCLOROTIAZIDA EN UNA CANTIDAD APROXIMADA DE 6,25 A 50 MG; Y ADITIVOS. SIENDO PREFERIDAS LAS FORMAS DE TABLETAS DE UNA SOLA CAPA; DE DOS CAPAS ASI POR EJEMPLO VALSARTAN E HIDROCLOROTIAZIDA EN UNA CAPA Y AMLODIPINO EN OTRA CAPA O VALSARTAN EN UNA CAPA Y AMLODIPINO E HIDROCLOROTIAZIDA EN OTRA CAPA; Y DE TRES CAPAS TENIENDO CADA INGREDIENTE EN CAPAS SEPARADAS. TAMBIEN SE REFIERE UN PROCEDIMIENTO DE ELABORACION. SIENDO UTILES EN EL TRATAMIENTO DE HIPERTENSION, ANGINA, EMBOLIA, DOLOR DE CABEZA, NEFROPATIA DIABETICA, INSUFICIENCIA RENAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80588306P | 2006-06-27 | 2006-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080991A1 true PE20080991A1 (es) | 2008-09-05 |
Family
ID=38662673
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001722A PE20120542A1 (es) | 2006-06-27 | 2007-06-25 | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
| PE2007000810A PE20080991A1 (es) | 2006-06-27 | 2007-06-25 | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001722A PE20120542A1 (es) | 2006-06-27 | 2007-06-25 | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20100003321A1 (es) |
| EP (1) | EP2037893A2 (es) |
| JP (1) | JP2009542709A (es) |
| KR (1) | KR20090021191A (es) |
| CN (2) | CN103169711A (es) |
| AR (1) | AR061627A1 (es) |
| AU (1) | AU2007265138A1 (es) |
| BR (1) | BRPI0713785A2 (es) |
| CA (1) | CA2654986A1 (es) |
| CL (1) | CL2007001870A1 (es) |
| EC (1) | ECSP088987A (es) |
| IL (1) | IL195797A0 (es) |
| MA (1) | MA30529B1 (es) |
| MX (1) | MX2008016532A (es) |
| NO (1) | NO20090314L (es) |
| NZ (1) | NZ573295A (es) |
| PE (2) | PE20120542A1 (es) |
| RU (1) | RU2449786C2 (es) |
| TN (1) | TNSN08538A1 (es) |
| TW (1) | TW200808379A (es) |
| WO (1) | WO2008002905A2 (es) |
| ZA (1) | ZA200810053B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3239B1 (ar) * | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
| US20120107397A1 (en) * | 2009-07-03 | 2012-05-03 | Hetero Research Foundation | Pharmaceutical compositions of valsartan |
| JP5758900B2 (ja) | 2009-09-30 | 2015-08-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル置換ベンジルベンゼン誘導体の調製方法 |
| UY32919A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
| CN102091069A (zh) * | 2009-12-11 | 2011-06-15 | 浙江华海药业股份有限公司 | 缬沙坦和氨氯地平的复方制剂及其制备方法 |
| CN101897675B (zh) * | 2010-02-10 | 2012-11-21 | 温士顿医药股份有限公司 | 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物 |
| CN101829111B (zh) * | 2010-05-23 | 2014-12-17 | 浙江华海药业股份有限公司 | 含有缬沙坦的固体制剂及其制备方法 |
| CN102716132B (zh) * | 2011-03-29 | 2015-09-30 | 石药集团中奇制药技术（石家庄）有限公司 | 复方氨氯地平/缬沙坦/氢氯噻嗪片及其制备方法 |
| KR20140108652A (ko) * | 2011-12-26 | 2014-09-12 | 노파르티스 아게 | 정제 및 건식-코팅된 작용제 |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102614190A (zh) * | 2012-04-17 | 2012-08-01 | 北京哈三联科技股份有限公司 | 含有缬沙坦、氨氯地平和氢氯噻嗪的片剂及其制备方法 |
| JP6018420B2 (ja) * | 2012-06-05 | 2016-11-02 | ニプロ株式会社 | アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物 |
| MX358211B (es) | 2012-07-23 | 2018-08-10 | Landsteiner Scient S A De C V | Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino. |
| CN103655580B (zh) * | 2012-08-28 | 2017-12-01 | 海南中济医药科技有限公司 | 一种含有缬沙坦、苯磺酸氨氯地平和氢氯噻嗪的药物组合物及其制备方法 |
| KR101778050B1 (ko) * | 2012-10-12 | 2017-09-13 | 이에이 파마 가부시키가이샤 | 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법 |
| CN102846625A (zh) * | 2012-10-18 | 2013-01-02 | 海口华仕联医药科技有限公司 | 一种稳定的缬沙坦、氨氯地平和氢氯噻嗪的药物组合及其制备方法 |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| ES2702174T3 (es) | 2013-04-05 | 2019-02-27 | Boehringer Ingelheim Int | Usos terapéuticos de empagliflozina |
| HK1213818A1 (zh) | 2013-04-05 | 2016-07-15 | 勃林格殷格翰国际有限公司 | 依帕列净的治疗用途 |
| HUE058731T2 (hu) | 2013-04-18 | 2022-09-28 | Boehringer Ingelheim Int | Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai |
| CZ2013783A3 (cs) | 2013-10-08 | 2015-04-15 | Zentiva, K. S | Stabilní farmaceutická kompozice obsahující amlodipin a valsartan |
| CN105106962A (zh) * | 2015-08-29 | 2015-12-02 | 西安力邦肇新生物科技有限公司 | 一种复方降压制剂及其应用 |
| WO2017207375A1 (en) * | 2016-05-30 | 2017-12-07 | Boehringer Ingelheim International Gmbh | Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine |
| KR20250097990A (ko) | 2016-11-10 | 2025-06-30 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 조성물, 치료 방법 및 이의 용도 |
| CA3053991A1 (en) | 2017-02-27 | 2018-08-30 | Idorsia Pharmaceuticals Ltd | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
| WO2019008485A1 (en) * | 2017-07-06 | 2019-01-10 | Mankind Pharma Ltd | FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL |
| EP3716979B1 (en) | 2017-11-30 | 2025-04-09 | Idorsia Pharmaceuticals Ltd | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases |
| WO2022132067A1 (en) * | 2020-12-18 | 2022-06-23 | Santa Farma Ilac Sanayii A.S. | Stable bilayer tablet compositions |
| CN113171352A (zh) * | 2021-04-15 | 2021-07-27 | 海南锦瑞制药有限公司 | 一种沙坦类降压复方制剂的制备方法 |
| GR1010320B (el) * | 2021-08-04 | 2022-10-11 | Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, | Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057344A (en) * | 1991-11-26 | 2000-05-02 | Sepracor, Inc. | Methods for treating hypertension, and angina using optically pure (-) amlodipine |
| EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
| RU2188636C2 (ru) * | 1998-03-26 | 2002-09-10 | Др. Редди'С Лабораторис Лтд. | Стабильный фармацевтический препарат, содержащий амлодипина безилат и атенолол |
| AU2002226365A1 (en) * | 2000-12-01 | 2002-06-11 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
| US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
| CN101352421A (zh) * | 2002-01-16 | 2009-01-28 | 贝林格尔英格海姆法玛两合公司 | 一种制备基本上非结晶形式的替米沙坦的方法 |
| US6869970B2 (en) | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
| AUPS236902A0 (en) * | 2002-05-16 | 2002-06-13 | Northern Sydney Area Health Service | Composition and method for treating hypertension |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| KR100580168B1 (ko) | 2003-03-21 | 2006-05-16 | 삼성전자주식회사 | 다중 홈 에이전트 제어장치 및 방법 |
| US20050209288A1 (en) | 2004-01-12 | 2005-09-22 | Grogan Donna R | Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use |
| JP5008565B2 (ja) | 2004-05-21 | 2012-08-22 | アキュ−ブレイク テクノロジーズ インコーポレーテッド | 相対的に不活性なセグメントを有する医薬錠剤 |
| PL1814527T5 (pl) * | 2004-11-05 | 2021-08-02 | Boehringer Ingelheim International Gmbh | Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę |
| CN100389830C (zh) * | 2005-05-08 | 2008-05-28 | 广州市施柏医药科技有限公司 | 一种治疗高血压的药物组合物 |
-
2007
- 2007-06-25 PE PE2011001722A patent/PE20120542A1/es not_active Application Discontinuation
- 2007-06-25 PE PE2007000810A patent/PE20080991A1/es not_active Application Discontinuation
- 2007-06-25 AR ARP070102798A patent/AR061627A1/es not_active Application Discontinuation
- 2007-06-26 CN CN2013100435988A patent/CN103169711A/zh active Pending
- 2007-06-26 KR KR1020087031581A patent/KR20090021191A/ko not_active Ceased
- 2007-06-26 BR BRPI0713785-0A patent/BRPI0713785A2/pt not_active IP Right Cessation
- 2007-06-26 CL CL200701870A patent/CL2007001870A1/es unknown
- 2007-06-26 WO PCT/US2007/072097 patent/WO2008002905A2/en active Application Filing
- 2007-06-26 EP EP07799032A patent/EP2037893A2/en not_active Ceased
- 2007-06-26 JP JP2009518503A patent/JP2009542709A/ja active Pending
- 2007-06-26 TW TW096123057A patent/TW200808379A/zh unknown
- 2007-06-26 MX MX2008016532A patent/MX2008016532A/es not_active Application Discontinuation
- 2007-06-26 AU AU2007265138A patent/AU2007265138A1/en not_active Abandoned
- 2007-06-26 NZ NZ573295A patent/NZ573295A/en not_active IP Right Cessation
- 2007-06-26 CA CA002654986A patent/CA2654986A1/en not_active Abandoned
- 2007-06-26 CN CN200780024142XA patent/CN101478956B/zh active Active
- 2007-06-26 RU RU2009102273/15A patent/RU2449786C2/ru not_active IP Right Cessation
- 2007-06-26 US US11/915,096 patent/US20100003321A1/en not_active Abandoned
-
2008
- 2008-11-26 ZA ZA200810053A patent/ZA200810053B/xx unknown
- 2008-12-08 IL IL195797A patent/IL195797A0/en unknown
- 2008-12-18 EC EC2008008987A patent/ECSP088987A/es unknown
- 2008-12-24 MA MA31506A patent/MA30529B1/fr unknown
- 2008-12-26 TN TNP2008000538A patent/TNSN08538A1/en unknown
-
2009
- 2009-01-20 NO NO20090314A patent/NO20090314L/no not_active Application Discontinuation
-
2012
- 2012-01-03 US US13/342,533 patent/US8475839B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101478956B (zh) | 2013-03-20 |
| NZ573295A (en) | 2012-01-12 |
| TNSN08538A1 (en) | 2010-04-14 |
| IL195797A0 (en) | 2009-09-01 |
| NO20090314L (no) | 2009-01-26 |
| AU2007265138A1 (en) | 2008-01-03 |
| KR20090021191A (ko) | 2009-02-27 |
| CN101478956A (zh) | 2009-07-08 |
| JP2009542709A (ja) | 2009-12-03 |
| US20120164218A1 (en) | 2012-06-28 |
| CL2007001870A1 (es) | 2008-06-13 |
| BRPI0713785A2 (pt) | 2012-10-30 |
| US8475839B2 (en) | 2013-07-02 |
| TW200808379A (en) | 2008-02-16 |
| RU2449786C2 (ru) | 2012-05-10 |
| WO2008002905A2 (en) | 2008-01-03 |
| CN103169711A (zh) | 2013-06-26 |
| MA30529B1 (fr) | 2009-06-01 |
| WO2008002905A3 (en) | 2008-12-11 |
| MX2008016532A (es) | 2009-01-19 |
| AR061627A1 (es) | 2008-09-10 |
| HK1133818A1 (en) | 2010-04-09 |
| RU2009102273A (ru) | 2010-08-10 |
| EP2037893A2 (en) | 2009-03-25 |
| US20100003321A1 (en) | 2010-01-07 |
| ECSP088987A (es) | 2009-01-30 |
| PE20120542A1 (es) | 2012-05-14 |
| CA2654986A1 (en) | 2008-01-03 |
| ZA200810053B (en) | 2009-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080991A1 (es) | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas | |
| CL2011001091A1 (es) | Forma de dosificacion farmaceutica oral solida que comprende en su nucleo nifedipino o nisoldipino y en un revestimiento de manto alrededor del nucleo al menos un antagonista de angiotensina ii y/o al menos un diuretico; procedimiento para su preparacion, util para tratar hipertension. | |
| AR054511A1 (es) | Una composicion que comprende emtricitabina y tenofovir df granuladas en seco | |
| AR063959A1 (es) | Formulaciones farmaceuticas en capas | |
| ECSP088188A (es) | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| AR103463A2 (es) | Formas de dosificación farmacéutica | |
| DK1749011T3 (da) | Bicykliske heterocykler som HIV-integrasehæmmere | |
| AR065096A1 (es) | Preparacion solida | |
| FI20090094L (fi) | Olmesartaanimedoksomiilin ja amlodipiinin kiinteä annostusmuoto | |
| FI20045495A0 (fi) | Monikerrosrakenne ja menetelmä sen valmistamiseksi | |
| CL2007003100A1 (es) | Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria. | |
| DK2679220T3 (da) | Osmotisk pumpe-tablet med kontrolleret porøsitet og fremgangsmåde til fremstilling deraf | |
| CL2010001362A1 (es) | Forma de dosificacion farmaceutica para la liberacion inmediata de la sustancia activa 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona-monoetanosulfonato; y su uso para el tratamiento y/o prevencion de enfermedades oncologicas e inmunologicas, entre otras. | |
| UY29845A1 (es) | Forma de dosificación osmótica con aspectos de liberación controlada y de liberación rápida | |
| CL2007003613A1 (es) | Compuestos nitroderivados, antagonistas del receptor de angiotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hipertension. | |
| CL2007003484A1 (es) | Composicion farmaceutica que comprende valsartan y un tensoactivo, un componente lipofilico y un componente hidrofilico; procedimiento de preparacion; y uso en el tratamiento de la insuficiencia cardiaca, angina, infarto de miocardio, arterioescleros | |
| ECSP066938A (es) | Composición farmacéutica que comprende una sal de mirtazapina | |
| CL2007001195A1 (es) | Composicion farmaceutica solida que comprende un nucleo con un compuesto derivado de bencimidazol y una grasa o aceite, una primera capa que comprende un polimero de alto peso molecular que recubre el nucleo y una segunda capa que comprende pioglitazona, util para tratar enfermedades circulatorias. | |
| SM200500011B (it) | Una composizione farmaceutica antimicobatterica | |
| CR8948A (es) | Composicion farmaceutica | |
| CL2007002524A1 (es) | Forma cristalina talfa de bromuro de (r)-3-(2-hidroxi-2,2-difenil-acetoxi)-1-(isoxazol-3-il-carbamoil-metil)-1-azonia-biciclo-[2.2.2]-octano; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso para el tratamiento de una en | |
| AR067498A1 (es) | Composicion farmaceutica estable de una sal hidrosoluble de vinorrelbina | |
| CO6331424A2 (es) | Formulacion farmaceutica de eprosartan | |
| CL2008001895A1 (es) | Composicion farmaceutica oral, fisicoquimicamente estable, en una unidad, que comprende besilato de amlodipino y pravastatina sodica; proceso de elaboracion; y uso en el tratamiento de hipertension arterial asociada a dislipidemia. | |
| PA8644501A1 (es) | Composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |